Shanghai Fosun Pharmaceutical Group Co Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company's product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III. It engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines. The company was founded in 1994 and is based in Shanghai, China.